Alnylam Pharma (DUL) Revenue

0 Followers

Alnylam Pharma Revenue

Alnylam Pharma had a revenue of 1.29B in the quarter ending Jun 30, 2026, with 10.60%. This bring the company's revenue in the last twelve months to 4.80B, Decreased 12.07%. In the fiscal year ending Dec 31, 2025, Alnylam Pharma had annual revenue of 3.71B with 65.19% growth.

Revenue (ttm)

4.80B

Revenue Growth

―

P/S Ratio

7.72

Revenue/Employee

CHF1,485,575

Employees

2,500

Market Cap

CHF28.69B

Revenue Chart

Revenue History

Fiscal End Date	Revenue	Change	Growth
Dec 31, 2025	3.71B	1.47B	+65.19%
Dec 31, 2024	2.25B	419.95M	+22.97%
Dec 31, 2023	1.83B	790.87M	+76.23%
Dec 31, 2022	1.04B	193.13M	+22.88%
Dec 31, 2021	844.29M	351.43M	+71.31%
Dec 31, 2020	492.85M	273.10M	+124.28%
Dec 31, 2019	219.75M	144.84M	+193.36%
Dec 31, 2018	74.91M	-15.00M	-16.69%
Dec 31, 2017	89.91M	―	―